Firering Strategic Minerals: From explorer to producer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
With all this noise, where’s Phil?
£26k buy the printed
should be interested next week
I'm still licking my wounds. Nothing constructive to add at this point - remain confident that they will secure a licencing deal before the lights go off, for what its worth.
Got 200k shares now, badly underwater obviously, but if they deliver a licencing deal (not sure where any of these rumors are coming from - suspect nobody knows anything and the pump and dump brigade have perhaps taken an interest in us), then obviously the upside could be absolutely ridiculous from these levels. We live in hope.
Fosun Pharma continues to develop CTX in stroke disability in China following the out-licensing agreement signed with ReNeuron in April 2019. In July 2022, ReNeuron announced that it had negotiated and signed a supplemental terms agreement with Fosun. As a result, the Group expects to receive approximately £1 million over the 24 month period from signing the agreement (including the £320,000 upfront payment received in January 2022) in relation to the initial supply of CTX cell bank vials and services provided to undertake the technology transfer, with up to a further £5 million receivable by the Group over the medium to longer term for the continued provision of CTX cell bank vials to enable manufacture by Fosun Pharma and with further potential milestone payments of up to £74m linked to the main agreement signed in 2019.
Fosun Pharma is expanding its cell therapy portfolio to stem cell platforms and ReNeuron CTX is one of the starting programmes. A dedicated Fosun Pharma team has been established for the technology transfer into China and the construction of a 20,000 square foot GMP facility to manufacture CTX is underway. The signing of this Supplemental Terms Agreement underscores Fosun Pharma's continued commitment to the CTX stroke disability programme.
The collaboration with Fosun Pharma continues on track and the Group continues to progress out-licensing opportunities for the CTX programme in other geographies.
Following the cessation of the hRPC programme earlier in the year, work has been ongoing to complete the data package that can be made available to potential interested parties. This data package is expected to be completed in Q4 2022. There has been some early interest in this programme and the Group will accelerate efforts to progress this once the data package is available.
Outlook
With the executive team now in place, the key focus over the coming period for myself and the rest for the team will be data generation and collaboration deals to further extend the cash runway.
We are targeting to announce several larger scale exosome collaborations from existing / new partners and to develop further collaboration agreements with our iPSC platform. We also plan to accelerate the number of partnering opportunities in the 'hopper' through a greater focus on marketing of the advantages of the CustomExTM platform. This, I believe, will lead to further success for the Company over the longer term.
The term ‘topping up’ is sometimes used by proponents of this stock, to reflect buys in the hundreds. Phil if you’re sitting on 200k I wish you well as I do others who similarly ‘put their money where their mouth is’. Good luck and a very good Christmas and new year.
Hi Phill I have 60K shares and in the same sinking boat as you. Been here since 2017 and was taken in by all the hype by the BOD and others on this board . Have learnt a expensive lesson over the 5 years but still hope for Reneuron to come good over the next 12 months but as I have said before the CFO does not have much of a hand to play to get a good deal over the next 12 months for the company or its long suffering shareholders, but we can all hope she can pull it off.
I am in the same boat Allenby. Slowly watching my investment disappear.
I this their 'Last chance saloon'.. ?
They have some deals pipelined and the Market Cap looks less than their current cash. I've averaged down this week using a dividend from elsewhere so that in my head at least, I'm not averaging down with anymore investing capital.
Not sure where all the shares from Richard Griffiths went but this is the current list of the top ten share holders in Reneuron.
Obotrita 7.83% ,Octopas 5.86% ,Rosetta cap 5.63 %, Arix cap 5.25% , The Invus 3.73% , Evans Sir Cristopher 2.45%, Evans Mark, 1.56% , Aberdeen Assets 1.03% Spreadex Ltd 0.73%
Richard Griffiths had 11.48% sold out on the 8th Dec now not listed as a share holder.